The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.
Recruiting
- Conditions
- Hematologic Diseases
- Registration Number
- NCT03868527
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
To identify the diagnostic and therapeutic approach (efficacy and toxicity) of patients with lymphoid malignant hemopathy who are managed in the hematology department.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 13000
Inclusion Criteria
- Patients followed for hematological diseases in Lyon Sud Hospital
Exclusion Criteria
- Patients who doesn't have hematological diseases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival 730 days Period between the end of the first treatment and the first confirmed relapse of lymphoma of patients who have received treatment to treat their lymphoma.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie treatment efficacy in lymphoid malignancies within the ARCAN database cohort?
How does retrospective data from NCT03868527 compare to standard-of-care outcomes in follicular lymphoma and diffuse large B-cell lymphoma?
Which biomarkers are associated with response prediction and patient selection in the ARCAN observational study of lymphoid cancers?
What adverse events are documented in the ARCAN database for patients with chronic lymphocytic leukemia and lymphoblastic lymphoma?
What combination therapies or novel targets are emerging in lymphoid malignancy research alongside the ARCAN database findings?
Trial Locations
- Locations (1)
Hôpital Lyon Sud
🇫🇷Pierre-Bénite, France
Hôpital Lyon Sud🇫🇷Pierre-Bénite, FranceGilles Salles, MDPrincipal Investigator